Alzheimer’s for Amateurs

Research Index entry · Trial

A slower start for donanemab cut brain swelling by about a third

Evidence
People · trial
Source
alzforum.org
Added
2 October 2026

What it is

Donanemab (Kisunla) is a drug given by drip that clears amyloid. In the TRAILBLAZER-ALZ 6 trial, starting it on a slower dose schedule cut ARIA-E, the brain swelling these drugs can cause, by about a third. In people with two copies of APOE4, the gene variant that raises both Alzheimer’s risk and swelling risk, it fell from 57 percent to 24 percent.

Where it stands

  1. Lab discovery
  2. Animal studies
  3. First studies in people
  4. Large trials
  5. Approved

An approved drug, now with a gentler way to start it, which eases the main worry families have about these drugs.

Update timeline

What changed

Newest first. Only changes to the subject itself appear here: new information, or something proven wrong.

  1. Watching
    The Scouts look again every Friday

    Only new information or a correction shows up here, not another mention of the same thing.

  2. Update

Educational, not medical advice. Spot something wrong? hello@alzamateurs.com